Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find Clinical Trials & Studies

ENO for non-ventilated COVID

I'm Interested!

Proof of Concept Safety Trial for S-Nitrosylation Therapy to Improve Oxygenation Status in Severe Covid-19 Patients Receiving Supplemental Oxygen Support

  • Sex at Birth: Any
  • Age: Adult (18 - 64), Older Adult (65+)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase I
  • Conditions Being Studied: Other Respiratory and Intrathoracic Organs, COVID-19

Study Purpose

ENO treatment has the potential to significantly improve the clinical management of patients with COVID-19 who are experiencing lung injury. In sum, ENO is a novel drug and its inhalation constitutes a unique therapeutic approach that has the potential to provide distinctive benefits to COVID-19 patients.

Principal Investigator
Robert Schilz DO
Department/Division
Pulmonary and Critical Care Medicine (Medicine)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

  • UH IRB: STUDY20210599
  • StudyID: 2021-0744
  • ClinicalTrials.gov: NCT04528771
I'm Interested!

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422